| Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis A Szeles, T Fazekas, S Vancsa, M Varadi, PT Kovacs, U Krafft, ... Cancer Immunology, Immunotherapy 72 (5), 1061-1073, 2023 | 21 | 2023 |
| High serum PD-L1 levels are associated with poor survival in urothelial cancer patients treated with chemotherapy and immune checkpoint inhibitor therapy U Krafft, C Olah, H Reis, C Kesch, C Darr, V Grünwald, S Tschirdewahn, ... Cancers 13 (11), 2548, 2021 | 20 | 2021 |
| The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy T Szarvas, A Csizmarik, M Váradi, T Fazekas, A Hüttl, P Nyirády, ... Urologic Oncology: Seminars and Original Investigations 39 (5), 296. e11-296 …, 2021 | 13 | 2021 |
| MMP-7 serum and tissue levels are associated with poor survival in platinum-treated bladder cancer patients T Szarvas, MJ Hoffmann, C Olah, E Szekely, A Kiss, J Hess, ... Diagnostics 11 (1), 48, 2020 | 13 | 2020 |
| Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas M Varadi, N Nagy, H Reis, B Hadaschik, C Niedworok, O Modos, ... Cancer medicine 12 (7), 9041-9054, 2023 | 8 | 2023 |
| Large Stokes-shift bioorthogonal probes for STED, 2P-STED and multi-color STED nanoscopy G Török, GB Cserép, A Telek, D Arany, M Váradi, L Homolya, ... Methods and Applications in Fluorescence 9 (1), 015006, 2020 | 7 | 2020 |
| Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer T Szarvas, A Csizmarik, N Nagy, D Keresztes, M Váradi, Z Küronya, ... Orvosi hetilap 161 (20), 813-820, 2020 | 7 | 2020 |
| Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer C Olah, H Reis, MJ Hoffmann, F Mairinger, S Ting, B Hadaschik, U Krafft, ... Cancer Medicine 12 (5), 5222-5232, 2023 | 6 | 2023 |
| Comprehensive analysis of the prognostic value of circulating MMP-7 levels in urothelial carcinoma: A combined cohort analysis, systematic review, and meta-analysis A Kubik, IPA das Virgens, A Szabo, M Varadi, A Csizmarik, A Keszthelyi, ... International Journal of Molecular Sciences 24 (9), 7859, 2023 | 5 | 2023 |
| Elevated pre-treatment serum MMP-7 levels are associated with the presence of metastasis and poor survival in upper tract urothelial carcinoma PT Kovács, T Mayer, A Csizmarik, M Váradi, C Oláh, Á Széles, ... Biomedicines 10 (3), 698, 2022 | 5 | 2022 |
| A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer—Stromal gene expressions show higher prognostic values … C Olah, C Hahnen, N Nagy, J Musial, M Varadi, G Nyiro, B Gyorffy, ... International Journal of Cancer 150 (5), 856-867, 2022 | 5 | 2022 |
| Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study M Váradi, O Horváth, O Módos, T Fazekas, CM Grunewald, G Niegisch, ... Scientific Reports 13 (1), 17378, 2023 | 3 | 2023 |
| Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer A Csizmarik, N Nagy, D Keresztes, M Váradi, T Bracht, B Sitek, K Witzke, ... Prostate Cancer and Prostatic Diseases 27 (3), 451-456, 2024 | 2 | 2024 |
| High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma Á Széles, PT Kovács, A Csizmarik, M Váradi, P Riesz, T Fazekas, ... Biomedicines 10 (10), 2560, 2022 | 2 | 2022 |
| Oncological relevance of gut and urine microbiomes C Oláh, M Váradi, O Horváth, P Nyirády, T Szarvas Orvosi Hetilap 162 (15), 579-586, 2021 | 2 | 2021 |
| Az áttétes kasztrációrezisztens prosztatarák gyógyszer-rezisztenciájának molekuláris vonatkozásai T Szarvas, A Csizmarik, N Nagy, D Keresztes, M Váradi, Z Küronya, ... Orvosi Hetilap 161 (20), 813-820, 2020 | 1 | 2020 |
| Combined analysis of molecular patterns and clinical factors for the prediction of immune checkpoint inhibitor therapy in advanced urothelial carcinoma T Szarvas, M Varadi, O Horvath, E Soos, T Fazekas, A Csizmarik, ... European Urology 85, S215-S216, 2024 | | 2024 |
| Real-world clinical data and gene expression analysis of urothelial carcinoma for the prediction of immune checkpoint inhibitor therapy T Szarvas, M Varadi, O Horvath, T Fazekas, A Csizmarik, I Kenessey, ... European Urology Open Science 56, S13, 2023 | | 2023 |
| Az urachuscarcinoma aktuális diagnosztikai és kezelési lehetőségei O Módos, M Váradi, B Dér, A Keszthelyi, M Szűcs, H Reis, P Nyirády, ... Orvosi Hetilap 164 (16), 602-609, 2023 | | 2023 |
| Current diagnostic and treatment strategies for urachal cancer O Módos, M Váradi, B Dér, A Keszthelyi, M Szűcs, H Reis, P Nyirády, ... Orvosi Hetilap 164 (16), 602-609, 2023 | | 2023 |
